A monoclonal antibody effective against the fibrosis observed in DMD

Partager sur

In DMD, the fibrosis observed in both skeletal muscle and myocardium is the most often irreversible outcome of a process of degeneration of the muscle fiber. 

American researchers have developed a monoclonal antibody directed against the LTBP4 protein which interacts with the growth factor TGFb. Using this antibody have resulted in: 

  • in vitro, stabilization of lesions of the membrane of isolated muscle fibers; 
  • decreased loss of muscle strength in mdx mice observed under eccentric exercise conditions;
  • a significant decrease in fibrosis, including in the diaphragmatic muscle.

 

Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy. Demonbreun AR, Fallon KS, Oosterbaan CC, et al. Sci Transl Med. 2021 (Sept). 13(610):eabf0376.

On the same topic